tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CRISM Therapeutics Forms Scientific Advisory Board for Glioblastoma Trial

Story Highlights
CRISM Therapeutics Forms Scientific Advisory Board for Glioblastoma Trial

Elevate Your Investing Strategy:

Amur Minerals ( (GB:CRTX) ) has shared an update.

CRISM Therapeutics Corporation has announced the establishment of a Scientific Advisory Board (SAB) to guide its upcoming clinical trial application for ChemoSeed in glioblastoma. The SAB, comprising experts in neuro-oncology, will provide valuable insights for the company’s Phase II clinical trial, potentially strengthening CRISM’s position in the oncology drug delivery market.

More about Amur Minerals

CRISM Therapeutics Corporation is a UK-based innovative drug delivery company focused on enhancing the clinical performance of cancer treatments for solid tumors through localized chemotherapy drug delivery. Its lead product, ChemoSeed, is designed to be implanted directly into tumors or resection margins, particularly in glioblastoma cases, to bypass the blood-brain barrier and ensure effective treatment.

Average Trading Volume: 63,207

Technical Sentiment Signal: Strong Buy

Current Market Cap: £1.61M

See more insights into CRTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1